Laxmi Dental Limited — PPTs, 27-05-2025: Investor Presentation

1. Financial Highlights:

Laxmi Dental reported revenue of INR 2391 Mn in FY25, up 24% YoY, driven by gross margin improving to 76.1%. EBITDA rose 76% to INR 419 Mn with a margin of 17.5%, while PAT grew 26% to INR 318 Mn, maintaining a 13.3% margin. Adjusted EBITDA, factoring in Kids-e-Dental, ESOP, and event expenses, reached INR 516 Mn (up 58%). Q4 margins softened due to ESOP and IDS event costs. Kids-e-Dental revenue declined slightly to INR 263 Mn. The balance sheet strengthened with lower net borrowings and cash & equivalents increasing to INR 908 Mn, supported by INR 698 Cr IPO proceeds.

2. Strategic Initiatives & Growth Drivers:

IPO proceeds are being used to automate and enhance manufacturing with advanced digital equipment including intraoral scanners. Focus remains on increasing digital dentistry adoption, expanding product launches, and growing branded sales across labs, aligners, and pediatric segments. Marketing efforts intensify with multi-channel campaigns and celebrity endorsements targeting both new and existing dental markets.

3. Business Developments:

The product portfolio expanded with new launches under Illusion and Taglus brands, plus US FDA approvals. The pediatric dental segment strengthened via a 60% stake in Kids-e-Dental LLP. Aligner solutions saw endogenous production of materials and equipment. Participation at the International Dental Show highlighted global ambitions. The dental network grew to 22,000+ clinics across 95+ countries and 300+ cities.

4. Market Position & Competitive Advantage:

Laxmi Dental stands as India’s only fully integrated dental products player with the second largest domestic lab and largest export lab. Its vertical integration and 64%+ digital penetration offer scale benefits. Leadership in pediatric crowns and B2B2C aligner solutions with US FDA clearances support growth in a market driven by rising awareness and technology adoption.

5. Investor Implications:

The firm’s strong topline growth, deleveraging, and targeted capacity/digital investments signal positive growth potential. A diverse product lineup and expanding dental network underpin sustainable margin gains. Investors should watch near-term margin pressure from one-off expenses and pediatric segment recovery, alongside execution risks in scaling and market penetration. Overall, strategic focus and market trends are supportive.